Zenas BioPharma Reports Positive Phase 3 INDIGO Open-Label Extension Data for Obexelimab in IgG4-RD
ZBIO sits 96% above its 52-week low of $13.5.
Summary
Zenas BioPharma announced new Phase 3 INDIGO open-label extension data showing sustained flare protection and reduced glucocorticoid toxicity for obexelimab in IgG4-RD, plus positive vaccine response sub-study results.
Key Events · Product Development and Regulatory · ZBIO
-
Phase 3 INDIGO Open-Label Extension Data
12-month flare-free probability of 0.93 (adjudicated) and 0.87 (investigator-determined) for obexelimab in IgG4-RD; median cumulative glucocorticoid rescue dose was 0 mg.
-
Reduced Glucocorticoid Toxicity
Obexelimab significantly reduced cumulative glucocorticoid toxicity vs placebo at week 52 (GTI Cumulative Worsening Score difference: -11.4; p=0.021).
-
Vaccine Response Sub-Study
Vaccination during a treatment-free window produced seroimmunity to influenza in 86% and COVID-19 in 100% of participants, with no disease flares observed.
-
Regulatory Context
Data add to the clinical evidence supporting obexelimab's BLA for IgG4-RD, which the FDA accepted in August 2026.
Analysis · ZBIO · Life Sciences
New Phase 3 INDIGO open-label extension data show obexelimab sustained flare protection over 12 months, with a 0.93 probability of remaining flare-free based on adjudicated flares. The drug also significantly reduced cumulative glucocorticoid toxicity versus placebo (GTI score difference -11.4, p=0.021), and a vaccine sub-study showed preserved immune responses during a treatment-free window. These results strengthen the case for obexelimab as a long-term, steroid-sparing therapy for IgG4-RD, a chronic disease affecting an estimated 25,000 U.S. patients. The data arrive as the company awaits FDA action on its BLA for obexelimab in IgG4-RD, accepted in August 2026, and ahead of Phase 2 SunStone topline results in SLE expected in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZBIO was trading at $26.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $13.50 to $44.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.